NFAT TFs influence CD19 CAR-T cell activation. Jurkat cells (3 × 10 7 cells/mL) were electroporated with pDNA, expressing CD19 CAR construct and tNFAT-based activators or …

Jan 29, 2018 · In this study, we demonstrate that CAR-T cells can be engineered to respond robustly to diverse soluble ligands, including the CD19 ectodomain, GFP variants, and …

Oct 25, 2021 · T cell activation was assessed using two independent assays: NFAT-Luc reporter gene expression and IL-2 production upon incubation with cognate antigen-bearing tumour …

Mar 29, 2019 · To test the functionality of NFAT-RE constructs, we used Jurkat and CD19-CAR-expressing Jurkat cells (Jurkat-1928z) as effector cells. We also used K562, CD19-expressing …

treatment of acute B cell lymphoblastic leukemia. When incubated with Raji (CD19+) target cells and increasing concentrations of blinatumomab, the TCR/CD3 Effector Cells (NFAT) show a …

Here, we developed a method for the external control over the activity of CD19 CAR-T cells based on engineered endogenous transcription factors (TFs) acting downstream of the CAR …

Apr 26, 2023 · Here we designed a system to control the proliferation and activation state of CARs based on downstream NFAT transcription factors, whose activity can be regulated via …

Jun 11, 2022 · Loss of SPPL3 results in hyperglycosylation of CD19, an alteration that directly inhibits CAR T cell effector function and suppresses anti-tumor cytotoxicity. Alternatively, over …

Using intravital imaging in an antigen-loss CD19-negative relapse xenograft model, we determined that CART123, but not CART19, recognized leukemic blasts, established …

Jul 25, 2023 · We found that the three anti-CD19 CARs (i.e., ζ, 28-ζ, and BB-ζ CAR) exhibited differential NFAT and NF-κB signaling dynamics in Jurkat and primary human T cells, where …